JONATHAN SLONIN - 03 Aug 2021 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Clinical Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
03 Aug 2021
Net transactions value
$0
Form type
4
Filing time
05 Aug 2021, 16:29:50 UTC
Previous filing
30 Jul 2021
Next filing
25 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Award $0 +5,000 +23% $0.000000 26,350 03 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $0 +10,000 $0.000000 10,000 03 Aug 2021 Common Stock 10,000 $60.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest in four equal annual installments beginning on August 1, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2 The stock option vests and becomes exercisable as to 25% of the option shares on July 20, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.